SCHEMBL25527231

SCHEMBL25527231

CO[C@H]1CC[C@H](C(=O)Nc2cccc(Br)n2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.56
ADORA3 P0DMS8 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
MAPK8 P45983 2/20 0.45
MAPK10 P53779 2/20 0.45
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
WNT1 P04628 3/20 0.41
GSK3B P49841 3/20 0.41
DYRK1A Q13627 3/20 0.41
ADORA2A P29274 2/20 0.41
ADORA1 P30542 2/20 0.41
ADORA2B P29275 1/20 0.41
MAPK14 Q16539 1/20 0.41
GRM5 P41594 1/20 0.40
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
ABL1 P00519 1/20 0.40
JAK1 P23458 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25527226 1.00 HPGD (0.56) HPGDADORA3SMN1; SMN2MAPK8MAPK10
SCHEMBL19439103 0.85 HPGD (0.77) HPGDADORA3SMN1; SMN2SLC6A2SLC6A4
SCHEMBL30052336 0.78 CTSC (0.44) HPGDSMN1; SMN2SLC6A2SLC6A4SLC6A3
SCHEMBL30052457 0.78 CTSC (0.44) HPGDSMN1; SMN2SLC6A2SLC6A4SLC6A3
SCHEMBL23885156 0.78 CTSC (0.44) HPGDSMN1; SMN2SLC6A2SLC6A4SLC6A3
SCHEMBL23885677 0.78 CTSC (0.44) HPGDSMN1; SMN2SLC6A2SLC6A4SLC6A3
SCHEMBL30052549 0.78 CTSC (0.44) HPGDSMN1; SMN2SLC6A2SLC6A4SLC6A3
SCHEMBL23885158 0.75 CFD (0.48) SLC6A2SLC6A4SLC6A3CFD
SCHEMBL1464415 0.74 HPGD (0.58) HPGDADORA3SMN1; SMN2SLC6A2SLC6A4
SCHEMBL23089299 0.72 HPGD (0.46) HPGDADORA3SMN1; SMN2MAPK8MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS C5, C9, C1QBP HPGD 808/4885ADORA3 1388/4885SMN1; SMN2 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.